Camallergy
London
About Camallergy
Camallergy (Cambridge Allergy Ltd) is a biopharmaceutical company dedicated to providing innovative, patient-centric treatments to address the millions of patients suffering worldwide from food allergies. Camallergy’s lead product is a novel oral immunotherapy for the treatment of peanut allergy designed to offer “bite-proof” protection to patients within 14 weeks of therapy. The Company’s unique intellectual property and treatment regimen are based on the clinical work initiated at Cambridge University Hospitals NHS Foundation Trust in Cambridge, UK.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $6.9M
- Last round: Equity Crowdfunding (Dec 2023)
- Website: camallergy.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Clinical Trials, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/camallergy-72902 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.